# Clinical Trial to Evaluate Safety and Efficacy of MesoCellA-Ortho Tissue-Engineered Advanced Therapy Product in Patients With Osteoarthrosis and Civilisation Diseases

Study · id `cardio:ct-nct05081921` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05081921](<https://clinicaltrials.gov/study/NCT05081921>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT05081921

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 1/2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 192 participants.

## Technical summary

Registry record NCT05081921. Randomized; quadruple masking; primary purpose treatment. Start 2022-01-05 (actual); primary completion 2024-02-20 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 1/2
- Enrolled: 192 participants (enrolled count; ClinicalTrials.gov record NCT05081921, source copy `cardio:ctgov-nct05081921-2024-03-21`, retrieved 2026-10-26)
- Started: 2022-01-05 (actual) (ClinicalTrials.gov record NCT05081921, source copy `cardio:ctgov-nct05081921-2024-03-21`, retrieved 2026-10-26)
- Primary completion: 2024-02-20 (actual) (ClinicalTrials.gov record NCT05081921, source copy `cardio:ctgov-nct05081921-2024-03-21`, retrieved 2026-10-26)
- Completion: 2024-02-20 (actual) (ClinicalTrials.gov record NCT05081921, source copy `cardio:ctgov-nct05081921-2024-03-21`, retrieved 2026-10-26)
- Countries: Poland (ClinicalTrials.gov record NCT05081921, source copy `cardio:ctgov-nct05081921-2024-03-21`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05081921-2024-03-21`, retrieved 2026-10-26)

## The registry's words

- Brief title: Clinical Trial to Evaluate Safety and Efficacy of MesoCellA-Ortho Tissue-Engineered Advanced Therapy Product in Patients With Osteoarthrosis and Civilisation Diseases
- Acronym: BioMiStem-CT
- Condition: Osteoarthritis of Knee
- Intervention (Drug): MesoCellA-Ortho administration
- Intervention (Drug): HA administration
- Lead sponsor: Jagiellonian University
- Lead sponsor class: OTHER
- Collaborator: National Center for Research and Development, Poland
- Collaborator class: OTHER
- Collaborator: KCRI
- Collaborator class: OTHER

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: Jagiellonian University (`cardio:org-jagiellonian-university`)
- Registry lists this organization as a collaborator: National Center for Research and Development, Poland (`cardio:org-national-center-for-research-and-development-poland`)

## Provenance

Content hash: bcaa422e8055d1d85419d5c5f060b21ce7e14c05a37e58a78fe2093b80180121
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
